World News: 13:30 GMT Wednesday 15th May 2019. [Atara Biotherapeutics, Inc. via Globe Newswire via SPi World News]
SOUTH SAN FRANCISCO, Calif., May 15, 2019 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases, today announced a presentation of initial ATA188 Phase 1 safety results for patients with progressive multiple sclerosis (MS) at the 5 Congress of the European Academy of Neurology (EAN), which will take place in Oslo, Norway, June 29 to July 2, 2019. ATA188, Atara’s off-the-shelf, allogeneic T-cell immunotherapy targets specific Epstein-Barr virus (EBV) antigens believed to play an important role in the pathogenesis of MS.
The primary objective of Atara’s ongoing ATA188 Phase 1 dose-escalating clinical study is to evaluate safety and tolerability for patients with progressive MS. Initial safety results showed that the first two dose cohorts of ATA188 were well tolerated with no dose-limiting toxicities and no grade ≥3 treatment-emergent adverse events. The study is continuing with the objective of identifying a recommended Phase 2 dose. In addition, a randomized double-blind, placebo-controlled dose-expansion period for this study is now planned following the completion of the dose escalation phase.
“We are encouraged by the initial ATA188 safety results from the first two dose cohorts,” said Dietmar Berger, M.D., Ph.D., Global Head of Research and Development of Atara Biotherapeutics. “We recently progressed to dosing patients with progressive MS in the fourth and final planned dose escalation cohort and look forward to presenting additional ATA188 safety results from this study at EAN in June.”
Key secondary endpoints of the Phase 1 study include measures of clinical improvement such as expanded disability status scale (EDSS) and MRI imaging as well as other clinical activity measures. The Phase 1 dose escalation period is expected to enroll a total of 24-30 primary and secondary progressive MS (PPMS, SPMS) patients in the U.S. and Australia. For more information about the study, please visit ClinicalTrials.gov ().
Details of the presentation are as follows:
John Grimaldi, Burns McClellan212-213-0006 x362
Globe Newswire: 13:30 GMT Wednesday 15th May 2019
SPi News is published by Sector Publishing Intelligence Ltd.
© Sector Publishing Intelligence Ltd 2019. [Admin Only]
Sector Publishing Intelligence Ltd.
Agriculture House, Acland Road, DORCHESTER, Dorset DT1 1EF United Kingdom
Registered in England and Wales number 07519380.